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Uncoupling proteins (UCPs) are mitochondrial proteins able to dissipate the proton gradient of the inner mitochondrial
membrane when activated. This decreases ATP-generation through oxidation of fuels and may theoretically decrease energy
expenditure leading to obesity. Evidence from Ucp(−/−) mice revealed a role of UCP2 in the pancreatic β-cell, because β-cells
without UCP2 had increased glucose-stimulated insulin secretion. Thus, from being a candidate gene for obesity UCP2 became
a valid candidate gene for type 2 diabetes mellitus. This prompted a series of studies of the human UCP2 and UCP3 genes with
respect to obesity and diabetes. Of special interest was a promoter variant of UCP2 situated 866bp upstream of transcription
initiation (−866G>A, rs659366). This variant changes promoter activity and has been associated with obesity and/or type 2
diabetes in several, although not all, studies. The aim of the current paper is to summarize current evidence of association of
UCP2 genetic variation with obesity and type 2 diabetes, with focus on the −866G>A polymorphism.
1.Introduction
Uncoupling protein 2 (UCP2) and uncoupling protein 3
(UCP3)belongtoalargefamily ofmitochondrialtransmem-
brane carriers. UCP2 was identiﬁed in 1997 based on its
homology to the brown fat uncoupling protein (UCP, then
renamed UCP1) [1, 2]. Shortly thereafter, UCP3 was cloned
also based on homology to UCP1 and UCP2 [3, 4]. Later,
more distantly related proteins were identiﬁed and named
UCP4 and UCP5 (BMCP1) [5–7]. The physiological role of
UCP1 is well established; it is responsible for nonshivering
thermogenesis in brown fat, in which it induces proton leak
across the inner mitochondrial membrane [8, 9]. Now 14
years later, the physiological functions of UCP2 and UCP3
are still under debate, as is the role of genetic variation
in these. The aim of this paper is to recapitulate the
currently published literature on human genetic variation
in the UCP2 genomic region concerning development of
obesity, type 2 diabetes, and related metabolic disorders
with focus on the −866G>A promoter polymorphism
(rs659366).
2.Physiological Functionsof UCP2and UCP3
UCP2 is ubiquitously expressed [1, 2]w h e r e a sU C P 3i s
found predominantly in skeletal muscle and brown adipose
tissue [3, 4, 10], and their expression is both induced by fast-
ing, and peroxisome proliferators as well as hyperglycemia,
which indicates a role connected with the availability of fuel
substrates [11–14]. However, the upregulation in response
to thyroid hormone, cold, β3-adrenergic agonists, and high
fat diets also suggests involvement in regulation of energy
expenditure [15–17].
Neither UCP2 nor UCP3 aﬀects basal proton con-
ductance of the mitochondrial inner membrane [18–23].
However, they do induce proton leak across the inner
mitochondrial membrane when activated by, for example,
fatty acids, superoxide, or free radical derived peroxidation
products of membrane phospholipids [24, 25]. UCP2 and
UCP3maydecreasetheformation ofsuperoxideandreactive
oxygen species (ROS) by mild uncoupling of the respiratory
chain, whose activity is increased under these circumstances
[21,24, 26](Figure 1).This is concordantwiththe induction2 Journal of Obesity
of UCP2 and UCP3during cold,fasting and high fat feeding,
since these conditions require lipid oxidation and thus high
activity of the respiratory chain [18]. On the other hand,
it has recently been suggested that UCP2 restricts pyruvate
eﬄux from the mitochondria and hence ensures availability
of substrates for the citric acid cycle, which would then
explain the increase in glucose oxidation compared with
lipid oxidation in Ucp2(−/−) mouse embryonic ﬁbroblasts
[27, 28] .W h e t h e rt h i sp r o p o s e df u n c t i o no fU C P 2i ss h a r e d
with UCP3 is not known, and this hypothesis requires more
investigation as it is less supported by experimental evidence
as the theory of mild uncoupling.
In the pancreatic β-cell, UCP2 is important for appro-
priate glucose-stimulated insulin secretion. Overexpression
of UCP2 inhibits glucose-stimulated insulin secretion in
pancreatic rat islets and INS-1 β-cells [36–38], which is
well explained by the theory of mild uncoupling because
the resulting decrease in ATP-levels decreases closure of
the ATP/ADP sensitive potassium channels, and therefore
decreases insulin secretion (Figure 1). Concordant with this,
Ucp2(−/−) mice have increased glucose-stimulated insulin
secretion and higher pancreatic islet ATP levels and are
protected against glucose-toxicity in β-cells [29, 39], and on
a high-fat diet they show increased insulin secretion and
decreased plasma triglyceride concentrations [40]. This is in
line with in vitro studies of Ucp2(−/−) islets of Langerhans,
which are resistant to palmitate-induced β-cell dysfunction
[41]. UCP2 mRNA is upregulated in obese ob/ob mice, and
ob/obmicelackingUCP2showedrestoredﬁrst-phase insulin
secretionand reducedlevelofhyperglycaemia [29].Noeﬀect
of Ucp2 gene disruption on obesity was observed, even
upon a high-fat diet or on a background of genetic obesity
[29, 32]; however, short-term inhibition of Ucp2 using
antisense oligonucleotidesameliorated insulin resistance and
improved insulin secretion in a diet-induced mouse model
[42]. Recently, β-cell function of Ucp2(−/−) on an in-bred
C57Bl background was reported to be opposite to earlier
published reports, in that β-cells without UCP2 showed
lower glucose-stimulated insulin secretion, but maintained
higher levels of reactive oxygen species [43]. The reason
for these contradictory results are at the moment unknown
but may be explained by yet unidentiﬁed modiﬁer genes
diﬀerent from the initial mixed C57Bl and 129 background
to congenic back-crossed strains [44]. Moreover, because
two diﬀerent theories exist for explaining the role of UCP2
in β-cells, it is diﬃcult to extrapolate from mouse data to
data obtained in humans. The speciﬁc contribution between
hypersecretion of insulin versus the deleteriouseﬀect of ROS
on β-cells in humans versus mice is unknown (Figure 1).
Similar to UCP2, UCP3 has recently been found to be
expressed in pancreatic β-cells, where it also inﬂuenced
insulin secretion [45], but the physiological function of
UCP3 in β-cells is not known.
Disruption of the UCP3 gene in mice does not cause an
obese phenotype, but levels of oxidative stress are increased
in skeletal muscle of Ucp3(−/−) mice [46, 47]. There may be
compensatory eﬀects when removing UCP3 or UCP2 from
skeletal muscle (or β-cells) in which they are coexpressed;
generation of UCP2 and UCP3 double knockout mice may
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Figure 1: Mechanism by which UCP2 activation may lead to
obesityandtype diabetes. UCP2upregulationbynutrients(glucose,
lipids, fatty acids, glutamine (protein-rich diet)) increases UCP2
mRNA transcription or translation. UCP2 activity is increased by
superoxide radicals. Increased UCP2 amount or activity causes β-
cell dysfunction [29] and may contribute to decreased metabolic
eﬃciency by decreasing ATP-generation. UCP2 activation decreases
oxidative stress and may therefore decrease aging [30], cancer
progression [31], and inﬂammation [32]. Decreased ROS levels
may also protect β-cell [33]. Decreased ATP-generation by UCP2
upregulation may cause less eﬃcient metabolism and protect
against obesity, which will decrease demand for insulin secretion
by the β-cell.
resolve this issue. Overexpression of UCP3 in skeletal muscle
or UCP3 together with UCP2 in skeletal muscle have been
reported to create a lean phenotype in mice [48, 49]. It
is uncertain whether these data are reliable as it has been
shown that overexpression of mitochondrial carriers may
lead to over-load of the inner mitochondrial membrane
and artifactual data [20]. Thus, over-expressing UCP2 or
UCP3 in mice may not be a good or reliable strategy for
interrogating their physiological function.
Interestingly,decreasedROSduetopartialuncouplingby
UCP2 or UCP3 could represent a link to the “thinness and
longevity” phenomenon observed when diet restriction of
rodentsincreases theirlife span byupto50%[50](Figure 1).
In fact, Ucp2(−/−) mice, having increased oxidative stress in
their mitochondria, live signiﬁcantly shorter than WT litter
mates [30], supporting the hypothesis that mitochondrial-
derived free radicals are involved in aging [51]. Recently,
it was shown that UCP2 mRNA levels were increased in
colon cancer samples, also suggesting a link between levels
of oxidative stress modulated by UCP2 and development of
cancer [52]( Figure 1).
3.UCPs: CandidateGenesfor
Obesity and Type2 Diabetes
BecauseUCP2andUCP3decreasemitochondrialmembrane
potential and mediate proton leak [53], they are candidate
genes for obesity and type 2 diabetes. UCP2 and UCP3 are
coexpressed inskeletalmuscle,which contributesthemostto
thebasal metabolicrate [54].MutationsreducingtheactivityJournal of Obesity 3
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Figure 2: Diagram of the UCP2-UCP3 genomic region with indications of common genetic variation. Genomic organization of the UCP2-
UCP3 region on chromosome 11. ATG: start codon, TGA: stop codon. Bent arrows indicate reported transcription start sites (from [34]).
UCP3 protein exists in a short and a long form due to alternative polyadenylation sites, indicated by TGAS and TGAL [35].
or expression of either protein could theoretically diminish
energy expenditure by an increase in coupling of oxidative
phosphorylation, and thereby contribute to development
of obesity. Mutations in UCP2 regulatory regions causing
increased levels could cause or worsen decreased glucose-
stimulated insulin secretion directly through a decreased
ATP/ADP ratio in the pancreatic β-cell and promote devel-
opment of type 2 diabetes.
The most consistent trait found in Ucp2(−/−) and
Ucp3(−/−) mice has been the increased levels of superoxide
radicals and oxidative stress. Insulin resistance may be
caused by increased intracellular ROS levels [55], which are
inﬂuenced by the expression or activity of UCPs [56]. UCP2
may also modulate the severity of low-grade inﬂammation
present in obesity and obesity-associated type 2 diabetes,
because ROS levels generated by macrophages and other
immune cells are increased in Ucp2(−/−) mice [32]. This
also points to an important role of UCP2 in atherosclerosis,
since Ucp2(−/−) mice fed an atherogenic diet developed
more atherosclerosis [57]. Similarly, oxidative stress may
be causative for late diabetic complications [58], and as
modulators of mitochondrial ROS levels, UCP2 and UCP3
may aﬀect the severity of diabetic complications.
4.HumanUCP2 and UCP3Genetic Variation
UCP2 and UCP3 are the likely result of an ancestral gene-
duplication, because they are situated close to each other
on chromosome 11q13 [64]( Figure 2). Because UCP2 and
UCP3 are considered candidate genes for development
of obesity and type 2 diabetes, they have been studied
extensively. There is a low number of frequent genetic
variants, which have been investigated in a large number of
studies (Table 1 and Figure 2), and most identiﬁed variants
have been of low frequency and have therefore not been
so intensively studied. There are 3 common polymorphisms
in UCP2, which are well studied: a promoter variant,
−866G>A (rs659366), a missense polymorphism in codon
55 changing an alanine to a valine (Codon 55Ala/Val,
rs660339), and a 45bp insertion-deletion polymorphism
in the 3 untranslated region (UTR) of the UCP2 gene
(3 UTRins/del). In UCP3, there is one common and
well-studied polymorphism: a promoter variant, −55C/T
(rs1800849) (Table 1)[ 63, 65–69].
5.Effectsof the −866G>AV a ri a n to n
TranscriptionalActivityof
theUCP2 Promoter
The −866G>A polymorphism is situated in the proxi-
mal promoter of UCP2 and putatively changes one or
more transcription factor binding sites [60, 70]. Several
studies determined whether the activity of the promoter
changes with genotype. In insulin producing cells, the β-
cell transcription factor PAX6 binds preferentially to the A-
allele, which increases reporter-gene activity of constructs
containing the A-allele [70, 71]. Sesti et al. (2003) showed
decreased glucose-stimulated insulin secretion from isolated
human islets having the GA-genotype vs. the GG-genotype
[72], suggesting that increased UCP2 mRNA from the A-
alleletranslates intoincreasedUCP2protein,inducedproton
leak, decreased ATP/ADP ratio, and decreased glucose-
stimulated insulin secretion in accordance with the pheno-
type of the Ucp2(−/−) mice. In adipocytes, the −866 A-allele
was associated with both decreased [73]o ri n c r e a s e d[ 74]
levels of adipose tissue UCP2 mRNA. However, reporter-
gene constructs with the −866 A-allele showed increased
activity in adipocytes [70], similar to ﬁndings in insulin-
producing cells. Thus, the minor A-allele directs higher rates
oftranscription fromtheUCP2promotercomparedwiththe
G-allele.
6.UCP2 GeneticVariationinRelation
to Obesity
The frequent −866G>A polymorphism (rs659366) has been
extensively investigated for association with obesity and4 Journal of Obesity
Table 1: Studied high frequency variants of the UCP2 and UCP3 genes.
Gene Variant Acc. number Approximate frequency (ref)
UCP2 Promoter −1957G>A rs649446 29.0% (A-allele) [59]
UCP2 Promoter −866G>A rs659366 37.0% (A-allele) [60]
UCP2 Codon 55Ala/Val rs660339 39.6% (Val) [61]
UCP2 3 UTR ins>del — 29.6% (ins-allele) [62]
UCP3 Promoter −55C>T rs1800849 26.9% (T-allele) [63]
UCP3 Exon 3 Tyr99Tyr rs1800006 30.0% (T-allele) [59]
UCP3 Exon 5 Tyr210Tyr rs2075577 16.0% (T-allele) [59]
related subphenotypes. The AAgenotypewas initially shown
to associate with a reduced risk of obesity among 596 and
791 white Europeans [74]—an observation that has been
replicated [75], but more studies report either increased
prevalenceoftheA-alleleinobesity[76–78]ornoassociation
at all [59, 60, 72, 79–88]( Table 2). The total number of
subjects in the studies reporting no association with obesity
for the A-allele is above 14000 and by far outnumbers
the initial observation, and the number of participants in
the three studies reporting association of the A-allele with
obesity or increasing indices of adiposity is approximately
4000. Therefore, it is most likely that the −866 A-allele has
a very modest eﬀect if any on development of obesity, but in
order to evaluate, this a proper meta-analysis is necessary.
Assuming that a more subtle intermediary obesity-
related phenotype is aﬀected by the −866G>A polymor-
phism, a number of observations have been made; among
681 French type 2 diabetic patients, the variant was
associated with elevated triglyceride and total cholesterol
concentrations and increased risk of dyslipidaemia [90],
and in line with this, decreased HDL-cholesterol levels were
reported among 658 Korean women [59].Lackofassociation
with lipid levels has also been reported [72, 79, 80, 82].
Carriers of the G-allele of the −866G>A polymorphism lost
more weight than A-homozygotes in a study of diet-induced
body fat reduction in 301 Korean women undergoing a very-
low-calorie programme [92]. Finally, in 296 obese children,
homozygosityoftheA-allele wasrelated to increased resting-
energy expenditure, increased glucose oxidation rate, and
lowerlipidoxidationrate[89],andamong185Pima Indians,
the −866G>A polymorphism was associated with increased
24-hour energy expenditure [83].
Numerous studies do not support a functional impact
of the 3 UTR insertion or the Ala55Val polymorphism in
causing obesity or type II diabetes. Few association studies
have found diﬀerences in allele or genotype frequencies of
the Ala55Val polymorphism between obese and/or type 2
diabetic subjects and control subjects [61, 93, 94]a n dt h i s
variant is generally not considered to predispose to obesity
or type 2 diabetes. The 3 UTR insertion polymorphism
has been related to measures of energy expenditure or
increased BMI [83, 95, 96]. In heterozygous state, the
3 UTR insertion has been associated with increased sleeping
metabolic rate and 24-h energy expenditure and lower BMI
in Pima Indians, in agreement with a role of UCP2 in
controlling energy expenditure [97]. Moreover, the insertion
homozygous genotype was associated with increased BMI
in South Indian females and increased serum leptin levels
in British women [95]. However, in Danish subjects there
was no association with obesity or weight gain over a 26-
year followup [62]. The 3 U T R4 5b pi n s e r t i o nc o u l de x e r t
its eﬀect through altered mRNA stability; however, there was
no diﬀerence in UCP2 mRNA levels between genotypes in
skeletal muscle from Pima Indians [97], but in vitro mRNA
stability assays showed that the insertion allele had less stable
mRNA [74].
7.Type 2 Diabetes and the Metabolic Syndrome
withRegardtoUCP2GeneticVariation
Mar Gonzalez-Barroso et al. (2008) reported on two families
in which congenital hyperinsulinemia occurred and who
carried heterozygous mutations in UCP2 [98]. The two
families each carried their own mutations, which segregated
with the disease and which changed amino acids conserved
between species. Functional studies of recombinant yeast
showed lower proton leak of the mutant UCP2s, and the
mutants were not able to suppress insulin secretion in β-
cells when over-expressed as opposed to wild-type UCP2.
Thus, the phenotype of carriers of heterozygous null-alleles
of UCP2 were in fact very similar to the phenotype of
Ucp2(−/−) mice on mixed-strain genetic background [29],
but opposite the phenotype of Ucp2(−/−) mice in congenic
lines[43].However,itisnotknown howthehyperinsulinism
associated with UCP2 null-mutations aﬀects β-cells later in
life; oxidative stress is increased in Ucp2(−/−) mice, and over
time this is associated with declining β-cell function. On the
other hand, Ucp2(−/−) mice do not become diabetic [43].
Thus, studying adult and aging carriers of the identiﬁed
UCP2mutationsislikelytobeveryrewarding forelucidating
the contribution of UCP2 towards maintenance of glucose
tolerance in humans.
GiventhatUCP2nullmutationscausehyperinsulinemia,
the −866 A-allele, having increased transcriptional activity,
would be expected to show association with decreased β-
cell function and ultimately with type 2 diabetes. When
examining measures of insulin secretion, the −866 A-allele
was associated with decreased glucose-stimulated insulin
secretion among 137 Japanese type 2 diabetic patients
undergoing frequently sampled IVGTT [71]a n da l s oi n
isolated pancreatic islets from nondiabetic subjects [72].Journal of Obesity 5
Table 2: Summary of association studies of the UCP2 promoter −866G>A (rs659366) polymorphism in relation to obesity and related
metabolic traits.
Ethnic
population
nobese
(Frequency
of A-allele
in %)
ncontrol
(Frequency
of A-allele
in %)
Phenotypes Reference
Caucasian 340 (46.5) 256 (52.2) CommonG-allele predisposed to obesity Esterbauer et al. 2001 [74]
109 (31.2) 589 (38.2)
Caucasian 749 (39.6) 816 (40.7) Not associated with obesity or BMI within groups Dalgaard et al. 2003 [60]
Caucasian 122 (28.2) 374 (29.0) Not associated with obesity or BMI within groups Mancini et al. 2003 [79]
76 (34.9)
Caucasian — 302 (32.1) Not associated with BMI within group Sesti et al. 2003 [72]
Caucasian — 565 (32.4) Not associated with BMI in control or diabetic patients D’Adamo et al. 2004 [80]
— 483 (33.6)
Japanese — 134 Not associated with BMI, but with hypertension Ji et al. 2004 [81]
342
Caucasian 296 (37.0) — A-allele associated with decreased lipid oxidation Le Fur et al. 2004 [89]
Caucasian — 327 (34.6) Not associated with BMI within group Bulotta et al. 2005 [82]
746 (28.6)
Pima 864 (54.0) — Not associated with BMI within group. AA genotype
increased 24hr EE
Kovacs et al. 2005 [83]
Indians 263 (55.5) —
Korean — 658 Not associated with BMI within group. Associated with
decreased HDL-levels Cha et al. 2007 [59]
Caucasian — 598 Not associated with BMI within group. A-allele associated
with decreased W/H-ratio and lower fasting p-insulin
Gable et al. 2007 [84]P
653
Filipino — 1755 (29.7) Not associated with BMI within group Marvelle et al. 2008 [85]
Caucasian 375 (41.3) 2316 (35.8)
A-allele associated with obesity and associated with increased
risk of CHD and systolic BP. AA genotype associated with
increased oxidative stress
Dhamrait et al. 2004 [77]
Caucasian 192 (38.3) 170 (38.2) AA genotype signiﬁcantly associated with obesity and insulin
resistance in children Ochoa et al. 2007 [76]
Caucasian 225 (39.6) 294 (38.9) AA genotype associated with various indices of obesity Kring et al. 2008 [78]
Caucasian 277 188 Not associated with early-onset obesity Sch¨ auble et al. 2003 [86]
Caucasian — 681 (36.9)
Not associated with BMI in type 2 diabetic patients, but AA
genotype associated with increased triglyceride and
cholesterol levels
Reis et al. 2004 [90]
Various — 3784
(35.4–46.7)
Not associated with obesity, allele-frequencies not given for
obese subjects Hsu et al. 2008 [87]
Korean — 1469 (∼48) GG genotype associated with obesity in children but
protective in adults Jun et al. 2009 [75]
Caucasian — 507 AA genotype decreased total cholesterol and decreased
LDL-cholesterol. Not associated with BMI within group Salopuro et al. 2009 [88]P
Indian 200 (42.0) 240 (32.2) A-allele associated with obesity and hyperinsulinemia (in
obese subjects) Srivastava et al. 2010 [91]
PDenotes prospective study. Abbreviations: CHD: coronary heart disease; BP: blood pressure; EE: energy expenditure; BMI: body mass index; HDL: high
densitylipoprotein; W/H: waist to hip.
These observations are in accordance with the A-allele
directing increased UCP2 expression and causing decreased
insulin secretion (but also lower ROS-levels). Decreased
basal insulin secretion was initially reported among A-allele
carriers [74] but was contrasted by subsequent studies [60,
72, 80–82], which showed no association. Also, early onset
of type 2 diabetes has been correlated with the A-allele
[71, 99], but also with the G-allele [100], whereas early
requirement for insulin treatment was observed in A-allele
carriers [71, 90]( Table 3).
Observations of a lower disposition index in −866A
carriers have been made [70, 72], although this could also
be induced by changes in insulin sensitivity rather than
insulin secretory capacity. It is possible that the −866 A6 Journal of Obesity
Table 3: Summary of association or prospective studies of the UCP2 promoter −866G>A (rs659366) polymorphism in relation to type 2
diabetes and intermediary phenotype.
Ethnic
population
ndiabetes
(Allele
frequency
in %)
ncontrol
(Allele
frequency
in %)
Phenotypes Reference
Caucasian 201 (41.2) 391 (32.5) A-allele associated with type 2 diabetes increased disposition index Krempler et al. 2002
[70]
Caucasian 565 (32.4) 483 (33.6) AA genotype decreased insulin sensitivity and was associated with
type 2 diabetes
D’Adamo et al. 2004
[80]
Caucasian — 2595 (37.0) AA genotype increased risk of type 2 diabetes, especially combined
with obesity
Gable et al. 2006
[99]P
Caucasian — 302 (28.8) A-allele associated with decreased insulin secretion. Isolated islets of
A-allele carriers had decreased in vitro insulin secretion Sesti et al. 2003 [72]
Caucasian 131 (33.0) 118 (48.0) G-allele associated with type 2 diabetes and increased adipose tissue
mRNA
Wang et al. 2004
[73]
Caucasian 746 (28.6) 327 (34.5) G-allele associated with type 2 diabetes Bulotta et al. 2005
[82]
Caucasian — 2216 (38.1) GG genotype increased risk of type 2 diabetes Lyssenko et al. 2005
[100]P
Indian 762 (35.0) 924 (41.0) G-allele associated with type 2 diabetes Rai et al. 2007 [101]
Caucasian — 3122 (36.7) GG genotype increased risk of MI in men Cheurfa et al. 2008
[102]P
Caucasian — 589 (38.2) AA genotype borderline associated with increased fasting insulin
levels
Esterbauer et al.
2001 [74]
Pima Indian 864 (54.0) — Not associated with type 2 diabetes within group. AA genotype
borderline associated with decreased insulin sensitivity
Kovacs et al. 2005
[83] 263 (55.5) —
Various 1584 2198
(35.4–46.7) Not associated with type 2 diabetes Hsu et al. 2008 [87]
Japanese 413 (47.2) 172 (43.1) Not associated with type 2 diabetes, but A-allele showed higher
transcriptional activity and carriers had decreased AIR
Sasahara et al. 2004
[71]
Caucasian — 235 (43.2) No associationwith changes fasting p-glucose or s-insulin in
glucose-tolerant subjects
Dalgaard et al. 2003
[60] 410 (34.5)
Caucasian — 507 AA genotype decreased total cholesterol and decreased
LDL-cholesterol.
Salopuro et al. 2009
[88]P
Caucasian — 296 (37.0) No inﬂuence on insulin sensitivity Le Fur et al. 2004
[89]
Caucasian 375 (41.3) 2316 (35.8) A-allele associated with increased type 2 diabetes risk, increased risk
of CAD and systolic BP, and increased oxidative stress
Dhamrait et al. 2004
[77]
Various — 901 (39.4) Diabetic A-allele carriers poor survival after MI Palmer et al. 2009
[103]P
Caucasian 453
(33.0–36.0) AA genotype associated with increased oxidative stress and CAD Stephens et al. 2008
[104]
Caucasian — 227 (39.3) Diab. neuropathy lower in AA genotype Rudofsky et al. [105]
Caucasian — 280 (39.3) GG genotype associated with low-grade inﬂammation,but not
insulin levels
Labayen et al. 2009
[106]
Caucasian — 383 (31.9) GG genotype associated with increased CRP Lapice et al. 2010
[107]
PDenotes prospective study. Disposition index: the product of Si and AIR. Abbreviations: Si: insulin sensitivity; AIR: acute insulin response; MI: myocardial
infarct; LDL: low density lipoprotein; CRP: C-reactive protein; CAD: coronary artery disease.
allele is involved in mediating decreased β-cell function
as well as decreased insulin sensitivity of adipose tissue,
which would be expected to translate into an increased risk
of type 2 diabetes. As the −866 A-allele was reported to
increase UCP2 mRNA expression [70, 71], it is expected
that ROS-levelswould be lower in A-carriers. However, since
insulin resistance is associated with increases in oxidative
stress [55], it is more likely that changes in disposition
index are due to diﬀerences in insulin secretion rather
than insulin resistance. In line with this, insulin resistanceJournal of Obesity 7
(HOMA-IR) has been reported to be positively correlated
with visceral adipose tissue UCP2 mRNA expression [80].
Followingthe“milduncouplingtheory”itwouldbeexpected
that increased UCP2 expression—as a possible consequence
of carrying the −866A-allele—would be associated with
increased insulin sensitivity. However, experimental studies
do not agree on the eﬀect of −866G>A on insulin sensitivity.
Using either hyperinsulinaemic-euglycaemic clamp or an
intravenous glucose tolerance test in 39, 263, and 181
subjects, respectively, AA genotype carriers were less insulin
sensitive [70, 80, 83], whereas in a number of other studies
insulin resistance estimated using the HOMA index in 632
Japanese subjects [81], 363 French adolescents [76], and 302
Italian subjects [72]w a sn o ta ﬀected by the UCP2 −866G>A
variant (Table 3). Clearly, more information is needed on
the physiological eﬀects of UCP2 on whole body insulin
sensitivity.
Association studies of type 2 diabetes have reported
association of the −866A-allele with increased risk of type
2 diabetes in studies representing up to 1640 subjects [70,
77, 80, 99], whereas other studies report association of the
G-allele with type 2 diabetes backed by studies of more
than 2700 subjects [73, 82, 100, 101], and a number of
large studies report no association of this variant with type
2d i a b e t e s[ 83, 87, 90]( Table 3). Prospective studies have
shown that subjects carrying the AA genotype were more
likely to become type 2 diabetic, or had poor survival
following myocardial infarction [77, 99, 103], but the G-
allele has also been associated with increased risk of type 2
diabetes [100]. Thus, it is necessary to perform more studies
as well as a proper meta-analysis to investigate the impact of
this variant on type 2 diabetes.
8.APossible Roleof −866G>A Variantand
OxidativeStressinCardiovascularDisease
and LateDiabeticComplications
Both increased risk of hypertension [81] as well as decreased
risk of dying following myocardial infarction [102, 103]h a s
beenreportedtobeassociatedwiththe−866Aallele,whereas
plasma total antioxidant status, which is low when oxidative
stress is increased, has been shown to be decreased in AA
genotype carriers. Among 2,695 healthy Caucasian men, the
risk of coronary heart disease and elevated diastolic blood
pressure was increased in men homozygous for the −866A-
allele while among 465 diabetic men, the A-allele was asso-
ciated with increased oxidative stress [77]—an observation
thatwassigniﬁcantlyaccentuatedbycigarettesmoking[104].
Thus, the functional A-allele, which mediates increased
UCP2 mRNA levels, is associated with increased oxidative
stress. This may be linked with the poor insulin secretion
associated with the AA-genotype, leading to increased levels
of plasma glucose and HbA1c [71], and perhaps oxidative
stress; however, this mechanism is speculative and needs
experimental validation. Also, low-grade inﬂammation has
been investigated in the context of the −866G>A poly-
morphism, where increased C-reactive protein (CRP) was
associated with the GG-genotype in a study of 283 diabetic
patients. In another study of 280 children and adolescents
CRP was unaltered, but ﬁbrinogen, complement C3 and
C4 were lower in AA-carriers [106]. Finally, Rudofsky et al.
(2006, 2007) showed increased prevalence of the G-allele in
type 1 diabetic patients, whereas there was no association
with microvascular complications [105, 108].
9.Possible InﬂuenceofOther SNPsin
theUCP2-UCP3Genomic Region
The genomic region containing the UCP2 and UCP3 genes
wereinvestigatedforatotalof14SNPs(including−866G>A)
spanning the UCP2 and UCP3 loci among 3,782 women
of diﬀerent ethnicities [87]. No single-SNP association
with type 2 diabetes was observed following correction
for multiple testing; yet, haplotype analysis indicated an
association with increased type 2 diabetes risk among 968
Caucasian women, and this eﬀect was further accentuated
by overweight although no direct association with BMI
was observed. The four-SNP haplotype in question was
in high LD with the −866 A-allele, suggesting that as yet
unidentiﬁed variation covered by the haplotype-spanned
area may be responsible for the observed relationships of
−866G>A with metabolic variables. The presence of other
functional variants may also account for the diﬀerence in
diabetesorobesityrisk-allelereportedbyanumberofstudies
(Tables 2 and 3).
10.ConclusionsandPerspectives
In acute studies using antisense oligonucleotides, UCP2 was
involved in both insulin secretion and insulin action [42],
whereas Ucp2(−/−) mice have not been reported to have
altered insulin sensitivity [29]. Studies of Ucp2(−/−) mouse
embryonic ﬁbroblasts have shown that loss of Ucp2 results
in increased glycolysis and decreased fatty acid oxidation—
suggesting that UCP2 regulates mitochondrial substrate
usagetoagreaterextentthanitsoriginalroleasan uncoupler
of respiratory chain activity from ATP synthesis [27, 28].
Absence ofUCP2 causes oxidativestress and superoxide pro-
duction [32, 39], which is associated with insulin resistance
[55]. However, a number of studies report association of the
high-expressing allele of the −866G/A variant with oxidative
stress, which is at odds with phenotype data from Ucp2(−/−)
mice. However, the widespread expression pattern makes
possible a dual function in obesity (energy metabolism) and
type 2 diabetes (glucose metabolism).
Withso many contrasting studiesthereis, agenuine need
for a thorough meta-analysis of the impact of the −866G>A
polymorphism in order to conclude whether it predisposes
to obesity and/or type 2 diabetes. It is important to note
that genome-wide association studies (GWAS) have not
identiﬁed SNPs in the UCP2-UCP3 locus as being associated
with obesity or type 2 diabetes [109, 110]. However, if the
mechanism of action of the −866G>A SNP, as some studies
indicate, occurs predominantly in already obese and type
2 diabetic subjects to increase late-diabetic complications,
such as cardiovascular disease via changes in oxidative stress8 Journal of Obesity
levels [77, 103–105], then this polymorphism is unlikely to
be identiﬁed through a GWAS strategy looking primarily at
obesity or type 2 diabetes. Furthermore, early disease onset
and a more frequent requirement for insulin may be related
to a reduced capacity of insulin secretion. It may well be that
the major contribution of genetic variability in UCP2 lies in
mediating susceptibility towards complications.
A main conclusion is that variation in the uncoupling
protein 2 gene is not associated with major alterations of
body weight or risk of type 2 diabetes. It is naturally more
diﬃcult to estimate the contribution of UCP genes towards
polygenic obesity and type 2 diabetes; however, although
manystudiesdoindicateassociation ofthe −866G>Avariant
with obesity and/or type 2 diabetes, the impact of this
single variant is low, as is the case with most predisposing
variants on polygenic traits. Therefore, large numbers of
well-characterised study subjects must be investigated to
d e t e c tt h et r u ee ﬀect of a given variant.
Sources
Google Scholar and PubMed were searched for publications
in English containing the words “uncoupling protein 2”,
“uncoupling protein 3”, “−866G/A”, “−55C/T”, “rs659366”,
“rs660339” “polymorphism”, “UCP2”, “UCP3”, “GWAS”,
“SNP”, and “proton leak”, alone or in combinations with
“obesity” and “diabetes”.
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